Quality control of CD4+ T-lymphocyte enumeration:: Results from the last 9 years of the United Kingdom National External Quality Assessment Scheme for Immune Monitoring (1993-2001)
Quality control of CD4+ T-lymphocyte enumeration:: Results from the last 9 years of the United Kingdom National External Quality Assessment Scheme for Immune Monitoring (1993-2001)
复制标题
DOI：
10.1002/cyto.10094
复制
发表时间：
2002-04-15
期刊：
影响因子：
--
通讯作者：
Barnett, D
中科院分区：
文献类型：
--
作者：
Whitby, L;Granger, V;Barnett, D
人类免疫缺陷病毒（HIV）的全球流行需要常规计数的T淋巴细胞亚群，这就需要外部质量保证（EQA）。英国国家免疫监测外部质量评估计划（UK NEQAS）为40个国家的296个实验室提供EQA。1993年，英国NEQAS开发并纳入其计划稳定的全血，使实验室性能的准确监测。总体而言，CD 4（+）T淋巴细胞亚群计数百分比的平均实验室间变异系数（CV）已从15%降至5%以下，这是增加使用CD 45/侧向散射（SSC）设门的直接结果。使用替代门控策略的实验室（即，CD 45/CD 14或前向散射[FSC]/SSC）的患者EQA检查失败的可能性约为7.4倍。此外，采用单平台技术导致绝对CD 4 + T淋巴细胞的总体平均实验室间CV从56%（单平台技术广泛使用之前）降至9.7%。还使用性能监测系统确定了个别实验室缺陷，并通过与协调中心合作进行再教育，圆满解决了这些缺陷。总之，在过去的9年中，英国NEQAS免疫监测计划强调了世界各地进行淋巴细胞亚群计数的实验室所取得的重大技术进步。Cytometry（Clin. Cytometry）50：102-110，2002年。(C)2002 Wiley-Liss，Inc.
The human immunodeficiency virus (HIV) global epidemic has necessitated the routine enumeration of T-lymphocyte subsets, which has created a need for external quality assurance (EQA). The United Kingdom National External Quality Assessment Scheme (UK NEQAS) for Immune Monitoring provides EQA for 296 laboratories in 40 countries. In 1993, UK NEQAS developed and incorporated into its program stabilized whole blood that enables the accurate monitoring of laboratory performance. Overall, the mean interlaboratory coefficient of variation (CV) for percentage CD4(+) T-lymphocyte subset enumeration has fallen from 15% to less than 5%, as a direct result of the increased use of CD45/ side scatter (SSC) gating. Laboratories using alternative gating strategies (i.e., CD45/CD14 or forward scatter [FSC]/SSC) were about 7.4 times more likely to fail an EQA exercise. Furthermore, the adoption of single-platform technology resulted in a reduction of the overall mean interlaboratory CV for absolute CD4+ T lymphocytes from 56% (prior to the widespread use of single-platform technology) to 9.7%. Individual laboratory deficiencies were also identified using a performance monitoring system and, through re-education by collaboration with the coordinating center, satisfactorily resolved. In conclusion, during the last 9 years, the UK NEQAS for Immune Monitoring program has highlighted the significant technological advances made by laboratories worldwide that undertake lymphocyte subset enumeration. Cytometry (Clin. Cytometry) 50:102-110, 2002. (C) 2002 Wiley-Liss, Inc.